EUCTR2009-012453-38-AT进行中（未招募）不适用
A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb - AGO 20
Studienzentrale AGO Austria0 个研究点开始时间: 2009年7月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Primary diagnosis of either adenocarcinoma or squamous small-cell or large-cell,
- •keratinizing or non-keratinizing carcinoma of the uterine cervix
- •Indication for primary chemoradiotherapy (both neoadjuvant and definitive treatment concepts are comprised) in patients with stage FIGO Ib-IIIb without paraaortic lymph node metastases, or with documented clinical indication for primary chemoradiotherapy
- •Absence of predominant and clinically effective neuroendocrine tumor cell differentiation
- •Absence of acute life-threatening vaginal hemorrhage (e.g. requiring emergency
- •irradiation, RBC packs transfusion)
- •Absence of clinical indication for paraaortic field irradiation because of (preferably)
- •histologically confirmed or unambiguous radiologic evidence of paraaortic lymph node
- •WHO performance status 0, 1 or 2
- •No current or prior malignancy within previous 5 years (other than current ovarian cancer or adequately treated non melanoma skin cancer or in-situ carcinoma of the cervix) Version 1.0 / AGO20 June 18, 2009 Page 11 of 78
- •Serum creatinine clearance >50 ml/min (measured or calculated)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenocarcinoma - Gastric 4MedDRA version: 12.1Level: LLTClassification code 10017764Term: Gastric cancer stage IIMedDRA version: 12.1Level: LLTClassification code 10017765Term: Gastric cancer stage IIIMedDRA version: 12.1Level: LLTClassification code 10017768Term: Gastric cancer stage IV without metastasesGastric cancerEUCTR2009-011337-27-ATAGMT
进行中（未招募）
不适用
A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. - LANDSCAPEEUCTR2008-001084-10-FRFNCLCC
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer. PANGEA-Breast”Patients with HER2-negative advanced breast cancer.MedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-001779-54-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)36
招募中
不适用
The Clinical Trial of Low Dose Irradiation for Alzheimer's DiseaseDiseases of the nervous systemKCT0007550Kyung Hee University Hospital at Gangdong60
招募中
不适用
A multicentre two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancerNeoplasmsKCT0006760Yonsei University Health System, Severance Hospital68